An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...

Pfizer's decision could stem from the fairly dismal performance of the only gene therapy for haemophilia A currently on the ...

Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 ...

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

Those key challenges impacting the care of respiratory diseases include delays in diagnosis due to the intermittent nature of ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement. The deal means that Agamree (vamorolone) will be available to ...

Eli Lilly will spend $3 billion expanding a recently acquired manufacturing facility in Wisconsin to provide capacity for injectable products, including its fast-growing obesity and diabetes drugs.

The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market. Ben Hargreaves finds that the early leaders, Gilead and Novartis, are now ...

Healthcare marketers looking for a fresh way to engage audiences across a wide range of demographics have turned to what may seem like an unusual source – sports. According to YouGov data, 67% ...